Key Takeaways Ultragenyx Q1 revenues fell 2% as Crysvita sales declined due to seasonal and ordering effects.RARE saw Evkeeza sales jump 64% on new country launches and early access demand.Ultragenyx expects FDA decisions on UX111 and DTX401 later in 2026 amid other pipeline progress.Ultragenyx Pharmaceutical (RARE) reported first-quarter 2026 loss of $1.84 per share, wider than the Zacks Consensus Estimate of a loss of $1.55. The company had incurred a loss of $1.57 per share in the year-ago quarter.Ultrag ...